Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness

Figure 1 Kaplan-Meier survival curves. A: Progression-free survival (PFS) of 30 patients; B: Overall survival of the whole cohort; C: PFS according to the patients with or without liver metastasis (P > 0.05); D: PFS according to previous exposure to regorafenib or not (P > 0.05). PFS: Progression-free survival; OS: Overall survival.

Figure 2 Receiver operating characteristics curves. A: The receiver operating characteristics curves of neutrophil-to-lymphocyte ratio; B: The receiver operating characteristics curves of platelet-to-lymphocyte ratio. NLR: Platelet -to-lymphocyte ratio; PLR: Neutrophil-to-lymphocyte ratio; ROC: Receiver operating characteristics.

Figure 3 Relationship between platelet-to-lymphocyte ratio and treatment response. A: Difference in platelet-to-lymphocyte ratio according to stable disease and progressive disease; B: Progression-free survival according to the platelet-to-lymphocyte ratio (P < 0.05). PLR: Platelet-to-lymphocyte ratio; PFS: Progression-free survival; SD: Stable disease; PD: Progressive disease.

Figure 4 Dynamic changes in carcinoembryonic antigen (μg/mL) and platelet-to-lymphocyte ratio after one and two treatment cycles. A: Carcinoembryonic antigen (μg/mL) in time in patients with stable disease; B: Carcinoembryonic antigen (μg/mL) in time in patients with progressive disease; C: Platelet-to-lymphocyte in time in patients with stable disease; D: Platelet-to-lymphocyte in time in patients with progressive disease. PLR: Platelet-to-lymphocyte ratio; SD: Stable disease; PD: Progressive disease.